Log in

NASDAQ:GLPGGALAPAGOS NV/S Stock Price, Forecast & News

-3.90 (-1.91 %)
(As of 05/25/2020 04:00 PM ET)
Today's Range
Now: $200.20
50-Day Range
MA: $211.64
52-Week Range
Now: $200.20
Volume242,218 shs
Average Volume99,648 shs
Market Capitalization$12.98 billion
P/E Ratio78.82
Dividend YieldN/A
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106; and Evotec AG for the novel target for fibrosis and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.17 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GLPG



Sales & Book Value

Annual Sales$1.00 billion
Cash Flow$6.25 per share
Book Value$58.75 per share


Net Income$167.83 million


Market Cap$12.98 billion
Next Earnings Date7/23/2020 (Estimated)

Receive GLPG News and Ratings via Email

Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.

GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions

How has GALAPAGOS NV/S's stock been impacted by COVID-19 (Coronavirus)?

GALAPAGOS NV/S's stock was trading at $186.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GLPG shares have increased by 7.6% and is now trading at $200.20. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of GALAPAGOS NV/S?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for GALAPAGOS NV/S.

When is GALAPAGOS NV/S's next earnings date?

GALAPAGOS NV/S is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for GALAPAGOS NV/S.

How were GALAPAGOS NV/S's earnings last quarter?

GALAPAGOS NV/S (NASDAQ:GLPG) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.09. The biotechnology company earned $117.93 million during the quarter, compared to the consensus estimate of $121.39 million. GALAPAGOS NV/S had a net margin of 15.42% and a return on equity of 12.45%. View GALAPAGOS NV/S's earnings history.

What price target have analysts set for GLPG?

16 Wall Street analysts have issued 12 month target prices for GALAPAGOS NV/S's shares. Their forecasts range from $155.00 to $298.00. On average, they anticipate GALAPAGOS NV/S's stock price to reach $229.00 in the next year. This suggests a possible upside of 14.4% from the stock's current price. View analysts' price targets for GALAPAGOS NV/S.

Has GALAPAGOS NV/S been receiving favorable news coverage?

News articles about GLPG stock have been trending very positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GALAPAGOS NV/S earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutGALAPAGOS NV/S.

Who are some of GALAPAGOS NV/S's key competitors?

What other stocks do shareholders of GALAPAGOS NV/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GALAPAGOS NV/S investors own include Gilead Sciences (GILD), CELYAD SA/ADR (CYAD), Intercept Pharmaceuticals (ICPT), argenx (ARGX), NVIDIA (NVDA), AbbVie (ABBV), Pharming Group (PHGUF), Trade Desk (TTD), Biogen (BIIB) and Collegium Pharmaceutical (COLL).

Who are GALAPAGOS NV/S's key executives?

GALAPAGOS NV/S's management team includes the following people:
  • Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 60)
  • Mr. Bart Filius MBA, CFO & COO (Age 49)
  • Dr. Piet Wigerinck, Chief Scientific Officer (Age 55)
  • Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. Communications
  • Dr. Andre Hoekema, Chief Bus. Officer (Age 62)


(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

What is GALAPAGOS NV/S's stock symbol?

GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."

Who are GALAPAGOS NV/S's major shareholders?

GALAPAGOS NV/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sands Capital Management LLC (3.44%), Federated Hermes Inc. (2.17%), BlackRock Inc. (0.49%), Bessemer Group Inc. (0.36%), Wellington Management Group LLP (0.20%) and Morgan Stanley (0.19%).

Which institutional investors are selling GALAPAGOS NV/S stock?

GLPG stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Wellington Management Group LLP, Federated Hermes Inc., Jane Street Group LLC, Bessemer Group Inc., Public Employees Retirement Association of Colorado, Wealth Quarterback LLC, and Peregrine Capital Management LLC.

Which institutional investors are buying GALAPAGOS NV/S stock?

GLPG stock was acquired by a variety of institutional investors in the last quarter, including Citigroup Inc., Morgan Stanley, BlackRock Inc., Acadian Asset Management LLC, United Capital Financial Advisers LLC, Envestnet Asset Management Inc., Parametric Portfolio Associates LLC, and JPMorgan Chase & Co..

How do I buy shares of GALAPAGOS NV/S?

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GALAPAGOS NV/S's stock price today?

One share of GLPG stock can currently be purchased for approximately $200.20.

How big of a company is GALAPAGOS NV/S?

GALAPAGOS NV/S has a market capitalization of $12.98 billion and generates $1.00 billion in revenue each year. The biotechnology company earns $167.83 million in net income (profit) each year or $5.46 on an earnings per share basis. GALAPAGOS NV/S employs 1,003 workers across the globe.

What is GALAPAGOS NV/S's official website?

The official website for GALAPAGOS NV/S is www.glpg.com.

How can I contact GALAPAGOS NV/S?

GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.